SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Mektix CHEWABLE 4 mg/10 mg film-coated tablets for small cats and kittens weighing at least 0.5 kg

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains:

Active substances:
Milbemycin oxime 4 mg
Praziquantel 10 mg

Excipients:

Qualitative composition of excipients and other constituents	**Quantitative composition if that information is essential for proper administration of the veterinary medicinal product**
Core	
Cellulose, microcrystalline	
Lactose monohydrate	
Povidone	
Croscarmellose sodium	
Silica, colloidal anhydrous	
Magnesium stearate	
Coat	
Hypromellose	
Talc	
Propylene glycol	
Titanium dioxide (E171)	0.21 mg
Liver Flavour	
Yeast powder	
Iron Oxide, yellow (E172)	0.18 mg
Iron Oxide, red (E172)	0.02 mg

Brownish orange, oval, biconvex film-coated tablets with score line on one side.
The tablets can be divided into halves.

3. CLINICAL INFORMATION

3.1 Target species

Cats (small cats and kittens).

3.2 Indications for use for each target species

Treatment of mixed infections by immature and adult cestodes and nematodes of the following species:

- Cestodes:
Dipylidium caninum
Taenia spp.
Echinococcus multilocularis

- Nematodes:
Ancylostoma tubaeforme
Toxocara cati

Prevention of heartworm disease (*Dirofilaria immitis*) if concomitant treatment against cestodes is indicated.

3.3 Contraindications

Do not use in cats of less than 6 weeks of age and/or weighing less than 0.5 kg.
Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

3.4 Special warnings

It is recommended to treat all the animals living in the same household concomitantly.

In order to develop an effective worm control programme local epidemiological information and the risk of exposure of the cat should be taken into account, and it is recommended to seek professional (e. g. veterinary) advice.

When *D. caninum* infection is present, concomitant treatment against intermediate hosts, such as fleas and lice, should be considered to prevent re-infection.

Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.

3.5 Special precautions for use

Special precautions for safe use in the target species:
No studies have been performed with severely debilitated cats or individuals with seriously compromised kidney or liver function. The veterinary medicinal product is not recommended for such animals or only according to a benefit/risk assessment by the responsible veterinarian.
Ensure cats and kittens weighing between 0.5 kg and ≤2 kg receive the appropriate tablet strength (4 mg milbemycin oxime/10 mg praziquantel) and the appropriate dose (1/2 or 1 tablet) for the corresponding weight band (1/2 tablet for cats weighing 0.5 to 1 kg; 1 tablet for cats weighing >1 to 2 kg).
As the tablets are flavoured, they should be stored in a safe place out of the reach of animals.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Accidental ingestion of a tablet by a child may be harmful. In order to prevent children from accessing the veterinary medicinal product, tablets should be administered and stored out of sight and reach of children.
Part tablets should be returned to the open blister pocket and inserted into the outer carton.
In case of accidental ingestion of one or more tablets, seek medical advice immediately and show the package leaflet or the label to the physician.
Wash hands after use.

Special precautions for the protection of the environment:
See also, section 5.5.

Other precautions:
Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the World Organisation for Animal Health (OIE), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority (e. g. experts or institutes of parasitology).

3.6 Adverse events

Cats (small cats and kittens):

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Systemic disorders (e.g. lethargy)* Neurological disorders (e.g. ataxia, muscle tremor)* Digestive tract disorders(e.g. diarrhoea, emesis)* Hypersensitivity reaction

*Especially in young cats

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national

competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:
Can be used during pregnancy and lactation.

Fertility:
Can be used in breeding cats.

3.8 Interaction with other medicinal products and other forms of interaction

No interactions were observed when the recommended dose of the macrocyclic lactone selamectin was administered during treatment with milbemycin oxime and praziquantel at the recommended dose. In the absence of further studies, caution should be taken in the case of concurrent use of the veterinary medicinal product and other macrocyclic lactones. Also, no such studies have been performed with reproducing animals.

3.9 Administration routes and dosage

Oral use.
To ensure a correct dosage, body weight should be determined as accurately as possible.
Minimum recommended dose rate: 2 mg of milbemycin oxime and 5 mg of praziquantel per kg are given orally as a single dose. The veterinary medicinal product should be administered with or after some food. Doing so ensures optimum protection against heartworm disease.
Depending on the bodyweight of the cat, the practical dosing is as follows:

Body weight	**Film-coated tablets for small cats and kittens**
0.5 - 1 kg	½ tablet
> 1 - 2 kg	1 tablet

The veterinary medicinal product can be inserted into a programme for prevention of heartworm disease if at the same time treatment against tapeworms is indicated. For the prevention of heartworm disease: the veterinary medicinal product kills *Dirofilaria immitis* larvae up to one month after their transmission by mosquitoes. For regular prevention of heartworm disease the use of a monosubstance is preferred.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

In case of overdose, in addition to signs observed at the recommended dose (see 3.6), drooling may be observed. This sign will usually disappear spontaneously within a day.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QP54AB51.

4.2 Pharmacodynamics

Milbemycin oxime belongs to the group of macrocyclic lactones, isolated from the fermentation of *Streptomyces hygroscopicus* var. *aureolacrimosus*. It is active against mites, against larval and adult stages of nematodes as well as against larvae of *Dirofilaria immitis*.

The activity of milbemycin is related to its action on invertebrate neurotransmission: Milbemycin oxime, like avermectins and other milbemycins, increases nematode and insect membrane permeability to chloride ions via glutamate-gated chloride ion channels (related to vertebrate $GABA_A$ and glycine receptors). This leads to hyperpolarisation of the neuromuscular membrane and flaccid paralysis and death of the parasite.
Praziquantel is an acylated pyrazino-isoquinoline derivative. Praziquantel is active against cestodes and trematodes. It modifies the permeability for calcium (influx of Ca^{2+}) in the membranes of the parasite inducing an imbalance in the membrane structures, leading to membrane depolarisation and almost instantaneous contraction of the musculature (tetany), rapid vacuolization of the syncytial tegument and subsequent tegumental disintegration (blebbing), resulting in easier expulsion from the gastrointestinal tract or death of the parasite.

4.3 Pharmacokinetics

In cats under fed condition, praziquantel reaches peak plasma concentrations within 3 hours after oral administration.
The half life of elimination is around 2 hours.

After oral administration in cats under fed condition, milbemycin oxime reaches peak plasma concentrations within 5 hours. The half life of elimination is around 43 hours (± 21 hours).

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Not applicable.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years
Shelf life for halved tablets after first opening the immediate packaging: 6 months.

5.3 Special precautions for storage

Store in the original package in order to protect from moisture.
This veterinary medicinal product does not require any special temperature storage conditions.
Store halved tablets below 25°C in the original blister and use for the next administration.

5.4 Nature and composition of immediate packaging

Blister packs consisting of cold formed OPA/Al/PVC foil and aluminium foil.
Cardboard box with 1 blister of 2 tablets.
Cardboard box with 1 blister of 4 tablets.
Cardboard box with 12 blisters, each blister contains 4 tablets (total 48 tablets).

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

The veterinary medicinal product should not enter water courses as milbemycin oxime may be dangerous for fish and other aquatic organisms.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

KRKA, d.d., Novo mesto

7. MARKETING AUTHORISATION NUMBER

Vm 01656/3051

8. DATE OF FIRST AUTHORISATION

09 April 2019

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

August 2023

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription (AT, CY, DE, DK, ES, FI, GR, HU, IE, IT, LV, PT, RO, UK (NI)).
Veterinary medicinal product not subject to prescription (BE, LT, NL).
Veterinary medicinal product subject to prescription except for some pack sizes (FR, SE).

Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).

Approved 09 August 2023